Confronting the barriers to develop novel vaccines against brucellosis

Expert Review of Vaccines

Volumn 10, Issue 9, 2011, Pages 1291-1305

  Oliveira, Sérgio Costa ^a   Giambartolomei, Guillermo Hernn ^b   Cassataro, Juliana ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Brucella abortus; brucellosis; DNA vaccine; live attenuated vaccine; recombinant protein vaccine; vaccine

Indexed keywords

BACTERIOFERRITIN; BRUCELLA VACCINE; COPPER ZINC SUPEROXIDE DISMUTASE; DNA VACCINE; HEAT SHOCK PROTEIN; HYBRID PROTEIN; LIVE VACCINE; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN 16; OUTER MEMBRANE PROTEIN 19; OUTER MEMBRANE PROTEIN 28; OUTER MEMBRANE PROTEIN 31; RECOMBINANT PROTEIN; RIBOSOME PROTEIN; SURA PROTEIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; BRUCELLA; BRUCELLOSIS; CONTROLLED STUDY; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; ARGENTINA; BRAZIL; BRUCELLA ABORTUS; BRUCELLA VACCINE; BRUCELLOSIS; CATTLE; FEMALE; GOVERNMENT REGULATION; HUMANS; MICE; MOLECULAR SEQUENCE DATA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SHEEP; TREATMENT OUTCOME; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 80052986244     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.110     Document Type: Review

References (125)

1. Carvalho Neta AV, Mol JP, Xavier MN et al. Pathogenesis of bovine brucellosis. Vet. J. 184(2), 146-155 (2010).
2. Pappas G, Akritidis N, Bosilkovski M et al. Brucellosis. N. Engl. J. Med. 352(22), 2325-2336 (2005).
3. Nicoletti, P. Vaccination against Brucella. Adv. Biotechnol. Processes 13, 147-168 (1990).
4. Nicoletti P. Vaccination. In: Animal Brucellosis. Nielsen K, Dunca JR (Eds). CRC Press, Boca Raton, FL, USA, 284-299 (1990).
5. Schurig GG, Roop RM 2nd, Bagchi T et al. Biological properties of RB51; a stable rough strain of Brucella abortus. Vet. Microbiol. 28(2), 171-188 (1991).
6. Marianelli C, Ciuchini F, Tarantino M et al. Genetic bases of the rifampin resistance phenotype in Brucella spp. J. Clin. Microbiol. 42(12), 5439-5443 (2004). (Pubitemid 39664317)
7. Moriyon I, Grillo MJ, Monreal D et al. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet. Res. 35(1), 1-38 (2004). (Pubitemid 38380146)
8. Adams LG. Development of live Brucella vaccines. In: Advances in Brucellosis Research. Adams LG (Ed.). Texas: A & M University Press, TX, USA, 205-276 (1990).
9. Dornand J, Gross A, Lafont V et al. The innate immune response against Brucella in humans. Vet. Microbiol. 90(1-4), 383-394 (2002). (Pubitemid 35279891)
10. Golding B, Scott DE, Scharf O et al. Immunity and protection against Brucella abortus. Microbes. Infect. 3(1), 43-48 (2001). (Pubitemid 32172039)
11. Kawai T, Akira S. TLR signaling. Semin. Immunol. 19, 24-32 (2007). (Pubitemid 46498752)
12. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 449(7164), 819-826 (2007). (Pubitemid 47598622)
13. Campos MA, Rosinha GM, Almeida IC et al. Role of Toll-like receptor 4 in induction of cell-mediated immunity and resistance to Brucella abortus infection in mice. Infect. Immun. 72(1), 176-186 (2004). (Pubitemid 38018175)
14. Weiss DS, Takeda K, Akira S et al. MyD88, but not Toll-like receptors 4 and 2, is required for efficient clearance of Brucella abortus. Infect. Immun. 73(8), 5137-5143 (2005). (Pubitemid 41105672)
15. Macedo GC, Magnani DM, Carvalho NB et al. Central role of MyD88-dependent dendritic cell maturation and proinflammatory cytokine production to control Brucella abortus infection. J. Immunol. 180 (2), 1080-1087 (2008).
16. Copin R, De Baetselier P, Carlier Y et al. MyD88-dependent activation of B220- CD11b+LY-6C+ dendritic cells during Brucella melitensis infection. J. Immunol. 178(8), 5182-5191 (2007). (Pubitemid 46595302)
17. Araya LN, Elzer PH, Rowe GE et al. Temporal development of protective cell-mediated and humoral immunity in BLAB/c mice infected with Brucella abortus. J. Immunol. 143, 3330-3337 (1989). (Pubitemid 20010164)
18. Oliveira SC, Splitter GA. CD8+ type 1 CD44hi CD45 RBlo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I- and class II-deficient mice. Eur. J. Immunol. 25(9), 2551-2557 (1995).
19. Oliveira SC, Harms JS, Rech EL et al. The role of T cell subsets and cytokines in the regulation of intracellular bacterial infection. Braz. J. Med. Biol. Res. 31, 77-84 (1998). (Pubitemid 128524614)
20. Murphy EA, Sathiyaseelan J, Parent MA et al. Interferon-g is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology 103(4), 511-518 (2001). (Pubitemid 32744399)
21. Jiang X, Baldwin CL. Effects of cytokines on intracellular growth of Brucella abortus. Infect. Immun. 61(1), 124-134 (1993). (Pubitemid 23015408)
22. Barquero-Calvo E, Chaves-Olarte E, Weiss DS et al. Brucella abortus uses a stealthy strategy to avoid activation of the innate immune system during the onset of infection. PLoS One 2(7), e631 (2007).
23. Fretin D, Fauconnier A, Kohler S et al. The sheathed flagellum of Brucella melitensis is involved in persistence in a murine model of infection. Cell. Microbiol. 7(5), 687-698 (2005). (Pubitemid 40585010)
24. Andersen-Nissen E, Smith KD, Strobe KL et al. Evasion of Toll-like receptor 5 by flagellated bacteria. Proc. Natl Acad. Sci. USA 102(26), 9247-9252 (2005). (Pubitemid 40923549)
25. Lapaque N, Muller A, Alexopoulou L et al. Brucella abortus induces Irgm3 and Irga6 expression via type-I IFN by a MyD88- dependent pathway, without the requirement of TLR-2, TLR-4, TLR-5 and TLR-9. Microb. Pathog. 47(6), 299-304 (2009).
26. Cardoso PG, Macedo GC, Azevedo V et al. Brucella spp noncanonical LPS: structure, biosynthesis, and interaction with host immune system. Microb. Cell. Fact. 5, 13 (2006).
27. Lapaque N, Moriyon I, Moreno E et al. Brucella lipopolysaccharide acts as a virulence factor. Curr. Opin. Microbiol. 8(1), 60-66 (2005). (Pubitemid 40203227)
28. Barquero-Calvo E, Conde-Alvarez R, Chacon-Diaz C et al. The differential interaction of Brucella and ochrobactrum with innate immunity reveals traits related to the evolution of stealthy pathogens. PLoS One 4(6), e5893 (2009).
29. Pei J, Turse JE, Ficht TA et al. Evidence of Brucella abortus OPS dictating uptake and restricting NF-kB activation in murine macrophages. Microbes. Infect. 10(6), 582-590 (2008).
30. Forestier C, Deleuil F, Lapaque N et al. Brucella abortus lipopolysaccharide in murine peritoneal macrophages acts as a down-regulator of T cell activation. J. Immunol. 165(9), 5202-5210 (2000).
31. Barrionuevo P, Cassataro J, Delpino MV et al. Brucella abortus inhibits major histocompatibility complex class II expression and antigen processing through interleukin-6 secretion via Toll-like receptor 2. Infect. Immun. 76(1), 250-262 (2008).
32. Porte F, Naroeni A, Ouahrani-Bettache S et al. Role of the Brucella suis lipopolysaccharide O antigen in phagosomal genesis and in inhibition of phagosomelysosome fusion in murine macrophages. Infect. Immun. 71(3), 1481-1490 (2003). (Pubitemid 36254335)
33. Pizarro-Cerda J, Meresse S, Parton RG et al. Brucella abortus transits through the autophagic pathway and replicates in the endoplasmic reticulum of nonprofessional phagocytes. Infect. Immun. 66(12), 5711-5724 (1998). (Pubitemid 28531826)
34. Celli J, de Chastellier C, Franchini DM et al. Brucella evades macrophage killing via VirB-dependent sustained interactions with the endoplasmic reticulum. J. Exp. Med. 198(4), 545-556 (2003). (Pubitemid 37040389)
35. Gorvel JP. Brucella: a Mr Hide converted into Dr Jekyll. Microbes. Infect. 10(9), 1010-1013 (2008).
36. Arellano-Reynoso B, Lapaque N, Salcedo S et al. Cyclic b-1,2-glucan is a Brucella virulence factor required for intracellular survival. Nat. Immunol. 6(6), 618-625 (2005). (Pubitemid 41710733)
37. Cirl C, Wieser A, Yadav M et al. Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/ interleukin-1 receptor domain-containing proteins. Nat. Med. 14(4), 399-406 (2008). (Pubitemid 351499388)
38. Radhakrishnan GK, Yu Q, Harms JS et al. Brucella TIR domain-containing protein mimics properties of the Toll-like receptor adaptor protein TIRAP. J. Biol. Chem. 284(15), 9892-9898 (2009).
39. Salcedo SP, Marchesini MI, Lelouard H et al. Brucella control of dendritic cell maturation is dependent on the TIRcontaining protein Btp1. PLoS Pathog. 4(2), e21 (2008).
40. Sengupta D, Koblansky A, Gaines J et al. Subversion of innate immune responses by Brucella through the targeted degradation of the TLR signaling adapter, MAL. J. Immunol. 184(2), 956-964 (2010).
41. Schijns VE. Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. 12, 456-463 (2000). (Pubitemid 30410353)
42. Lima KM, dos Santos SA, Rodrigues JM Jr et al. Vaccine adjuvant: it makes the difference. Vaccine 22(19), 2374-2379 (2004). (Pubitemid 38757332)
43. Reed SG, Bertholet S, Coler RN et al. New horizons in adjuvants for vaccine development. Trends Immunol. 30, 23-32 (2009).
44. Oliveira SC, Splitter GA. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine 14(10), 959-962 (1996). (Pubitemid 26271067)
45. Mallick AI, Singha H, Chaudhuri P et al. Liposomised recombinant ribosomal L7/ L12 protein protects BALB/c mice against Brucella abortus 544 infection. Vaccine 25, 3692-3704 (2007). (Pubitemid 46584754)
46. Mallick AI, Singha H, Khan S et al. Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis. Vaccine 25, 7873-7884 (2007). (Pubitemid 350011001)
47. Yang Y, Yin J, Guo D et al. Immunization of mice with recombinant S-adenosyl-lhomocysteine hydrolase protein confers protection against Brucella melitensis infection. FEMS Immunol. Med. Microbiol. 61(2), 159-167 (2011).
48. Velikovsky CA, Goldbaum FA, Cassataro J et al. Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used. Infect. Immun. 71, 5750-5755 (2003). (Pubitemid 37205628)
49. Zylberman V, Craig PO, Klinke S et al. High order quaternary arrangement confers increased structural stability to Brucella sp. lumazine synthase. J. Biol. Chem. 279, 8093-8101 (2004). (Pubitemid 38294699)
50. Berguer PM, Mundinano J, Piazzon I et al. A polymeric bacterial protein activates dendritic cells via TLR-4. J. Immunol. 176, 2366-2372 (2006). (Pubitemid 43201685)
51. Velikovsky CA, Cassataro J, Giambartolomei GH et al. A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infect. Immun. 70, 2507-2511 (2002). (Pubitemid 34408394)
52. Cassataro J, Estein SM, Pasquevich KA et al. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Infect. Immun. 73, 8079-8088 (2005). (Pubitemid 41740295)
53. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 19, 2666-2672 (2001). (Pubitemid 32234287)
54. Kwissa M, Kasturi SP, Pulendran B. The science of adjuvants. Expert Rev. Vaccines 6(5), 673-684 (2007). (Pubitemid 47607845)
55. Denisov AA, Korobovtseva YS, Karpova OM et al. Immunopotentiation of live brucellosis vaccine by adjuvants. Vaccine 1(28), 17-22 (2010).
56. Al-Mariri A, Tibor A, Mertens P et al. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect. Immun. 69, 4816-4822 (2001). (Pubitemid 32674460)
57. Kaushik P, Singh DK, Kumar SV et al. Protection of mice against Brucella abortus challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides. Vet. Res. Commun. 34, 119-132 (2010).
58. Cassataro J, Velikovsky CA, Giambartolomei GH et al. Immunogenicity of the Brucella melitensis recombinant ribosome recycling factor-homologous protein and its cDNA. Vaccine 20, 1660-1669 (2002). (Pubitemid 34169809)
59. Leclerq S, Harms JS, Rosinha GM et al. Induction of a Th1-type of immune response but not protective immunity by intramuscular DNA immunisation with Brucella abortus GroEL heat-shock gene. J. Med. Microbiol. 51, 20-26 (2002). (Pubitemid 34060129)
60. Bae JE, Schurig GG, Toth TE. Mice immune responses to Brucella abortus heat shock proteins. Use of baculovirus recombinant-expressing whole insect cells, purified Brucella abortus recombinant proteins, and a vaccinia virus recombinant as immunogens. Vet. Microbiol. 88, 189-202 (2002). (Pubitemid 34804790)
61. Demotz S, Moulon C, Roggero MA et al. Native-like, long synthetic peptides as components of sub-unit vaccines: practical and theoretical considerations for their use in humans. Mol. Immunol. 38, 415-422 (2001). (Pubitemid 34008471)
62. Tabatabai LB, Pugh GW Jr. Modulation of immune responses in Balb/c mice vaccinated with Brucella abortus Cu-Zn superoxide dismutase synthetic peptide vaccine. Vaccine 12, 919-924 (1994).
63. Vizcaino N, Kittelberger R, Cloeckaert A et al. Minor nucleotide substitutions in the omp31 gene of Brucella ovis result in antigenic differences in the major outer membrane protein that it encodes compared with those of the other Brucella species. Infect. Immun. 69, 7020-7028 (2001). (Pubitemid 32995462)
64. Delpino MV, Estein SM, Fossati CA et al. Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine 25, 6721-6729 (2007). (Pubitemid 47342467)
65. Cassataro J, Pasquevich KA, Estein SM et al. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine 25, 4437-4446 (2007). (Pubitemid 46695804)
66. Dagan R, Eskola J, Leclerc C et al. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect. Immun. 66, 2093-2098 (1998). (Pubitemid 28194107)
67. Singh RA, Rodgers JR, Barry MA. The role of T cell antagonism and original antigenic sin in genetic immunization. J. Immunol. 169, 6779-6786 (2002). (Pubitemid 36899262)
68. Laplagne DA, Zylberman V, Ainciart N et al. Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides. Proteins 57, 820-828 (2004). (Pubitemid 39627004)
69. Delpino MV, Marchesini MI, Estein SM et al. A bile salt hydrolase of Brucella abortus contributes to the establishment of a successful infection through the oral route in mice. Infect. Immun. 75, 299-305 (2007). (Pubitemid 46047905)
70. Pasquevich KA, Estein SM, Samartino CG et al. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Infect. Immun. 77, 436-445 (2009).
71. Yang X, Walters N, Robison A et al. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. Vaccine 25, 2261-2268 (2007). (Pubitemid 46227696)
72. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 11, 45-53 (2005).
73. Pasquevich KA, Garcia Samartino C, Coria LM et al. The protein moiety of Brucella abortus outer membrane protein 16 is a new bacterial pathogen-associated molecular pattern that activates dendritic cells in vivo, induces a Th1 immune response, and is a promising self-adjuvanting vaccine against systemic and oral acquired brucellosis. J. Immunol. 184, 5200-5212 (2010).
74. Pasquevich KA, Ibanez AE, Coria LM et al. An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice. PLoS One 6(1), e16203 (2011).
75. Vogel FR. Improving vaccine performance with adjuvants. Clin. Infect. Dis. 3, 266-270 (2000).
76. Sala F, Manuela Rigano M, Barbante A et al. Vaccine antigen production in transgenic plants: strategies, gene constructs and perspectives. Vaccine 21, 803-808 (2003). (Pubitemid 36092002)
77. Shewen PE, Carrasco-Medina L, McBey BA et al. Challenges in mucosal vaccination of cattle. Vet. Immunol. Immunopathol. 128, 192-198 (2009).
78. Feltquate DM, Heaney S, Webster RG et al. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 158, 2278-2284 (1997). (Pubitemid 127470012)
79. Pertmer TM, Eisenbraun MD, McCabe D et al. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 13, 1427-1430 (1995).
80. Tighe H, Corr M, Roman M et al. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today 19, 89-97 (1998). (Pubitemid 28097655)
81. Gurunathan S, Wu CY, Freidag BL et al. DNA vaccines: a key for inducing long-term cellular immunity. Curr. Opin. Immunol. 12, 442-447 (2000). (Pubitemid 30410351)
82. Kurar E, Splitter GA. Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response. Vaccine 15, 1851-1857 (1997). (Pubitemid 27504679)
83. Al-Mariri A, Tibor A, Mertens P et al. Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp. Infect. Immun. 69, 6264-6270 (2001). (Pubitemid 32885190)
84. Leclercq SY, Oliveira SC. Protective immunity induced by DNA-library immunization against an intracellular bacterial infection. J. Drug Target 11, 531-538 (2003). (Pubitemid 38519163)
85. Leclercq S, Harms JS, Oliveira SC. Enhanced efficacy of DNA vaccines against an intracellular bacterial pathogen by genetic adjuvants. Curr. Pharm. Biotechnol. 4, 99-107 (2003). (Pubitemid 36416867)
86. Oñate AA, Cespedes S, Cabrera A et al. A DNA vaccine encoding Cu, Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice. Infect. Immun. 71, 4857-4861 (2003). (Pubitemid 37070726)
87. Munoz-Montesino C, Andrews E, Rivers R et al. Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells. Infect. Immun. 72, 2081-2087 (2004). (Pubitemid 38419921)
88. Cassataro J, Pasquevich KA, Estein SM et al. A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine 25, 5958-5967 (2007). (Pubitemid 47082464)
89. Cassataro J, Velikovsky CA, de la Barrera S et al. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect. Immun. 73, 6537-6546 (2005). (Pubitemid 41368818)
90. Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis vaccines: past, present and future. Vet. Microbiol. 90, 479-496 (2002). (Pubitemid 35282500)
91. Luo DY, Li P, Xing L et al. DNA vaccine encoding L7/L12-P39 of Brucella abortus induces protective immunity in BALB/c mice. Chin. Med. J. (Engl.) 119, 331-334 (2006). (Pubitemid 47034004)
92. Yu DH, Li M, Hu XD et al. A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector. Vaccine 25, 6744-6754 (2007). (Pubitemid 47332727)
93. Yu DH, Hu XD, Cai H. A combined DNA vaccine encoding BCSP31, SOD, and L7/ L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses. DNA Cell Biol. 26, 435-443 (2007). (Pubitemid 46981698)
94. Hu XD, Chen ST, Li JY et al. An IL-15 adjuvant enhances the efficacy of a combined DNA vaccine against Brucella by increasing the CD8+ cytotoxic T cell response. Vaccine 28(12), 2408-2415 (2010).
95. Perkins SD, Smither SJ, Atkins HS. Towards a Brucella vaccine for humans. FEMS Microbiol. Rev. 34, 379-394 (2010).
96. Ramsay AJ, Kent SJ, Strugnell RA et al. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunol. Rev. 171, 27-44 (1999). (Pubitemid 29504710)
97. Gonzalez-Smith A, Vemulapalli R, Andrews E et al. Evaluation of Brucella abortus DNA vaccine by expression of Cu-Zn superoxide dismutase antigen fused to IL-2. Immunobiology 211, 65-74 (2006). (Pubitemid 43153701)
98. Singha H, Mallick AI, Jana C et al. Escheriosomes entrapped DNA vaccine co-expressing Cu-Zn superoxide dismutase and IL-18 confers protection against Brucella abortus. Microbes. Infect. 10, 1089-1096 (2008).
99. Rosinha GM, Myioshi A, Azevedo V et al. Molecular and immunological characterisation of recombinant Brucella abortus glyceraldehyde-3- phosphatedehydrogenase, a T- and B-cell reactive protein that induces partial protection when co-administered with an interleukin- 12-expressing plasmid in a DNA vaccine formulation. J. Med. Microbiol. 51, 661-671 (2002). (Pubitemid 34804290)
100. Commander NJ, Spencer SA, Wren BW et al. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Vaccine 25, 43-54 (2007). (Pubitemid 44855244)
101. Ramshaw IA, Ramsay AJ. The prime- boost strategy: exciting prospects for improved vaccination. Immunol. Today 21, 163-165 (2000). (Pubitemid 30184783)
102. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 25, 98-104 (2004). (Pubitemid 38167491)
103. Cassataro J, Velikovsky CA, Bruno L et al. Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting. Clin. Vaccine Immunol. 14, 869-874 (2007).
104. Luo D, Ni B, Li P et al. Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice. Infect. Immun. 74, 2734-2741 (2006). (Pubitemid 43672982)
105. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Ann. Rev. Immunol. 18, 927-974 (2000). (Pubitemid 30365401)
106. Ingolotti M, Kawalekar O, Shedlock DJ et al. DNA vaccines for targeting bacterial infections. Expert Rev. Vaccines 9(7), 747-763 (2010).
107. Saez D, Guzman I, Andrews E et al. Evaluation of Brucella abortus DNA and RNA vaccines expressing Cu-Zn superoxide dismutase (SOD) gene in cattle. Vet. Microbiol. 129, 396-403 (2008).
108. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9(10), 776-788 (2008).
109. Barrio MB, Grilló MJ, Muñoz PM et al. Rough mutants defective in core and O-polysaccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against Brucella melitensis infection of sheep. Vaccine 27(11), 1741-1749 (2009).
110. González D, Grilló MJ, De Miguel MJ et al. Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export. PLoS One 3(7), e2760 (2008).
111. Ugalde JE, Comerci DJ, Leguizamón MS et al. Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a new live rough-phenotype vaccine. Infect. Immun. 71(11), 6264-6269 (2003). (Pubitemid 37337683)
112. Lacerda TL, Cardoso PG, Augusto de Almeida L et al. Inactivation of formyltransferase (wbkC) gene generates a Brucella abortus rough strain that is attenuated in macrophages and in mice. Vaccine 28(34), 5627-5634 (2010).
113. Grilló MJ, Manterola L, de Miguel MJ et al. Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants. Vaccine 24(15), 2910-2916 (2006).
114. Izadjoo MJ, Bhattacharjee AK, Paranavitana CM et al. Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M. Infect. Immun. 72(7), 4031-4039 (2004). (Pubitemid 38821918)
115. Izadjoo MJ, Mense MG, Bhattacharjee AK et al. A study on the use of male animal models for developing a live vaccine for brucellosis. Transbound. Emerg. Dis. 55(3-4), 145-151 (2008). (Pubitemid 351530884)
116. Tibor A, Jacques I, Guilloteau L et al. Effect of P39 gene deletion in live Brucella vaccine strains on residual virulence and protective activity in mice. Infect. Immun. 66(11), 5561-5564 (1998). (Pubitemid 29044661)
117. Kahl-McDonagh MM, Ficht TA. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infect. Immun. 74(7), 4048-4057 (2006). (Pubitemid 43993337)
118. Rajashekara G, Glover DA, Banai M et al. Attenuated bioluminescent Brucella melitensis mutants GR019 (virB4), GR024 (galE), and GR026 (BMEI1090- BMEI1091) confer protection in mice. Infect. Immun. 74(5), 2925-2936 (2006). (Pubitemid 43673003)
119. Arenas-Gamboa AM, Ficht TA, Kahl- McDonagh MM et al. The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infect. Immun. 77, 877-884 (2009).
120. Trant CG, Lacerda TL, Carvalho NB et al. The Brucella abortus phosphoglycerate kinase mutant is highly attenuated and induces protection superior to that of vaccine strain 19 in immunocompromised and immunocompetent mice. Infect. Immun. 78(5), 2283-2291 (2010).
121. Cheville NF, Stevens MG, Jensen AE et al. Immune responses and protection against infection and abortion in cattle experimentally vaccinated with mutant strains of Brucella abortus. Am. J. Vet. Res. 54(10), 1591-1597 (1993). (Pubitemid 23338460)
122. Fiorentino MA, Campos E, Cravero S et al. Protection levels in vaccinated heifers with experimental vaccines Brucella abortus M1-luc and INTA 2. Vet. Microbiol. 132(3-4), 302-311 (2008).
123. Edmonds M, Booth N, Hagius S et al. Attenuation and immunogenicity of a Brucella abortus htrA cycL double mutant in cattle. Vet. Microbiol. 76(1), 81-90 (2000). (Pubitemid 30484049)
124. Poester FP, Gonalves VS, Lage AP. Brucellosis in Brazil. Vet. Microbiol. 90(1-4), 55-62 (2002). (Pubitemid 35282497)
125. Samartino LE. Brucellosis in Argentina. Vet. Microbiol. 90(1-4), 71-80 (2002). (Pubitemid 35279870)